203 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA
Tender Offer Completed for Soleno Therapeutics Shares at $53.00 Each
Other Events
To Acquire, Expanding Its Endocrinology and Rare Disease Portfolio
Board Approves Amended and Restated Bylaws on March 16, 2026
Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
Executive Compensation Increases Approved for Soleno Therapeutics
Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results
Q1
FY 2024
Q3
Q2
FY 2023
Administrative Withdrawal
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-8 POS